#Exon20
LightNews LightNews
sbgrid.bsky.social
SBGrid's eLife paper received a citation from Michael Eck from @danafarber.bsky.social in @pnas.org : Biochemical analysis of EGFR exon20 insertion variants insASV and insSVD and their inhibitor sensitivity.

Read more here: https://buff.ly/4g1rbWc

#ScienceMatters #SBGrid
buff.ly
December 18, 2024 at 5:00 PM
cancergrace.bsky.social
Mensajes para llevar a casa de la presentación de nuestra querida Dra. @Latinamd

#CáncerDePulmón #EGFR #Exon20 #GRACE
August 15, 2026 at 4:58 PM
jordixiol.bsky.social
Amivantamab + lazertinib showed survival benefit over osimertinib in 1L NSCLC with classical EGFR mutations

www.targetedonc.com/view/amivant...

Meanwhile sunvozertinib, an amivantamab contender in exon20 EGFR-mutated NSCLC, was granted priority review by the FDA

www.onclive.com/view/sunvoze...
www.targetedonc.com
January 7, 2025 at 9:22 PM
c-b-c-hungary.bsky.social
Orális célzott szer csökkentette a progresszió kockázatát a kemoterápiához képest EGFR exon 20 NSCLC esetén
Egy megerősítő elsővonalbeli vizsgá...

https://www.calorie-bank.com/nutrition-news.html?article=medpagetoday-egfr-exon20-2026-05-29&lang=hu

Download: https://apps.apple.com/app/id6759676528
Orális célzott szer csökkentette a progresszió kockázatát a kemoterápiához képest EGFR exon 20 NSCLC esetén
June 2, 2026 at 10:14 AM
togaanz.bsky.social
Read the blog > buff.ly/mP6vEOh
DEFIANT: A new clinical trial for EGFR exon20 insertion lung cancer - TOGA - Thoracic Oncology Group Australasia
The DEFIANT trial will evaluate datopotamab deruxtecan (Dato-DXd) in EGFR exon 20 insertion NSCLC after targeted therapy and chemotherapy.
thoraciconcology.org.au
August 26, 2026 at 11:01 PM
togaanz.bsky.social
What could the next step be for patients with EGFR exon 20 insertion lung cancer after targeted therapy and chemotherapy?

TOGA’s Phase II DEFIANT trial will evaluate datopotamab deruxtecan (Dato-DXd) in patients with EGFR exon 20 insertion NSCLC.
https://thoraciconcology.org.au/news/clinical-trials/defiant-egfr-exon20-insertion-clinical-trial-dato-dxd/
thoraciconcology.org.au
August 26, 2026 at 11:01 PM
hhorinouchi.bsky.social
🔜 #ELCC26 @myesmo.bsky.social
🔥Don’t miss the target: BRAF, HER2, METex14 and EGFR exon20 in focus
☑️ #BRAF #HER2 #METex14 #EGFRex20ins
🎙️Chair: Dr. Caicun Zhou, Dr. Natasha Leighl
@oncoalert.bsky.social LARVOL #LCSM
March 17, 2026 at 12:17 PM
stocktitan.net
#AVBP ArriVent’s Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026

https://www.stocktitan.net/news/AVBP/arri-vent-s-topline-pivotal-phase-3-furvent-data-for-firmonertinib-rvf8oj0otwhs.html
AVBP - Arrivent Biopharma Inc Latest Stock News & Market Updates
ArriVent BioPharma (AVBP) news hub: Track clinical trials, FDA milestones & oncology innovations. Your source for EGFR inhibitor developments & biopharma updates.
www.stocktitan.net
July 21, 2025 at 12:00 PM
covalentmod.bsky.social
Highly Optimized CNS Penetrant Inhibitors of EGFR Exon20 Insertion Mutations https://covalentmodifiers.blogspot.com/2025/01/highly-optimized-cns-penetrant.html
January 30, 2025 at 7:00 PM
covalentmod.bsky.social
Discovery of STX-721, a Covalent, Potent, and Highly Mutant-Selective EGFR/HER2 Exon20 Insertion Inhibitor for the Treatment of Non-Small Cell Lung Cancer https://covalentmodifiers.blogspot.com/2025/01/discovery-of-stx-721-covalent-potent.html
January 21, 2025 at 6:00 PM
l2plabs.bsky.social
Dizal Completes Enrollment for its Phase III Pivotal Study of Sunvozertinib vs. Platinum Doublet in Treatment Naïve NSCLC Patients with EGFR Exon20 Insertional Mutations
SHANGHAI, June 19, 2025 /PRNewswire/ -- Dizal announced the completion of patient enrollment for its WU-KONG28 clinical trial: a multinational, randomized phase III study evaluating the efficacy and safety of sunvozertinib versus platinum-based doublet chemotherapies as a first-line...
dlvr.it
June 19, 2025 at 10:09 AM